Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 + QS-21 extension in Alzheimer's
NCT00960531Phase 2
Key facts
- Status
- Terminated
- Start
- Jul 2009
- Primary completion
- Dec 2013
- Countries
- 1
- Sponsor
- Pfizer
- Modality
- Antibody Conjugates, Peptide-based Cancer Vaccines
- Drugs
- vanutide cridificar
- Conditions
- Alzheimer's disease (AD)
01
Overview
Phase 2, randomised, double-blind trial of vanutide cridificar in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoint: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) at 24 months. Started Jul 2009; status: terminated.
02
Design
3 arms- Study design
- RandomizedDouble-blind
ACC-001 (3mcg) + QS-21
ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
ACC-001 (10mcg) + QS-21
ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
ACC-001 (30mcg) + QS-21
ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
03
Who it enrols
Subjects randomized under previous 3134K1-2201 study (NCT00498602) with mild to moderate Alzheimer's disease.
04
Endpoints
Primary
Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs)
Beyond the preview
Go deeper on NCT00960531.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00960531.